Thomas Steyer’s Avita Medical RCEL Stock Holding History

Thomas Steyer’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-580,000	Closed	-$2.75M	–	320
2022 Q2	$2.75M	Sell	580,000 -220,000	-28%	-$1.36M	0.01%	201
2022 Q1	$6.78M	Hold	800,000	–	–	0.03%	171
2021 Q4	$9.58M	Hold	800,000	–	–	0.05%	135
2021 Q3	$14.2M	Hold	800,000	–	–	0.07%	122
2021 Q2	$16.4M	Hold	800,000	–	–	0.07%	107
2021 Q1	$15.9M	Buy	+800,000	New	+$18.6M	0.08%	113

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Thomas Steyer's RCEL Position: Q3 2022 in Review

Thomas Steyer sold out of Avita Medical (RCEL) in Q3 2022, closing a stake of 580,000 shares — an estimated $2.75M sold.

Thomas Steyer first reported a position in RCEL in Q1 2021 and held it in 6 quarters. The position peaked at $16.4M in Q2 2021. 48 funds tracked by Wall St. Rank hold RCEL as of Q3 2022.

Thomas Steyer reported no remaining Avita Medical position as of Q3 2022 after selling out during the quarter.
Thomas Steyer sold 580,000 Avita Medical shares in Q3 2022, an estimated $2.75M.
Thomas Steyer first reported a position in Avita Medical in Q1 2021 and held it in 6 quarters.
Thomas Steyer's Avita Medical position peaked at $16.4M in Q2 2021.
48 funds tracked by Wall St. Rank held Avita Medical as of Q3 2022.

Based on Farallon Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.